MX9705025A - Proteinas de matriz nuclear de vejiga y su uso para detectar y tratar trastornos proliferativos celulares. - Google Patents

Proteinas de matriz nuclear de vejiga y su uso para detectar y tratar trastornos proliferativos celulares.

Info

Publication number
MX9705025A
MX9705025A MX9705025A MX9705025A MX9705025A MX 9705025 A MX9705025 A MX 9705025A MX 9705025 A MX9705025 A MX 9705025A MX 9705025 A MX9705025 A MX 9705025A MX 9705025 A MX9705025 A MX 9705025A
Authority
MX
Mexico
Prior art keywords
cell proliferative
proliferative disorders
matrix proteins
detecting
nuclear matrix
Prior art date
Application number
MX9705025A
Other languages
English (en)
Inventor
Robert H Getzenberg
Robert R Bahnson
Original Assignee
Robert H Getzenberg
Robert R Bahnson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Robert H Getzenberg, Robert R Bahnson filed Critical Robert H Getzenberg
Publication of MX9705025A publication Critical patent/MX9705025A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se proveen proteínas de matriz nuclear (PMN) que se caracterizan por una expresion definida en tejido de vejiga. Estas PMN son marcadores utiles en el diagnostico y monitoreo del estado de malignidad y tratamiento de trastornos proliferativos de células de la vejiga. También se proveen polipéptidos y secuencias de polipéptidos substancialmente purificados que codifican las PMN de la invencion.
MX9705025A 1995-11-03 1996-11-01 Proteinas de matriz nuclear de vejiga y su uso para detectar y tratar trastornos proliferativos celulares. MX9705025A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US622695P 1995-11-03 1995-11-03
PCT/US1996/017119 WO1997016206A1 (en) 1995-11-03 1996-11-01 Bladder nuclear matrix proteins and their use in detecting and treating cell proliferative disorders

Publications (1)

Publication Number Publication Date
MX9705025A true MX9705025A (es) 1998-05-31

Family

ID=21719882

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9705025A MX9705025A (es) 1995-11-03 1996-11-01 Proteinas de matriz nuclear de vejiga y su uso para detectar y tratar trastornos proliferativos celulares.

Country Status (8)

Country Link
US (1) US5866535A (es)
EP (1) EP0810874A4 (es)
JP (1) JPH10512158A (es)
AU (1) AU7474696A (es)
BR (1) BR9607575A (es)
CA (1) CA2209314A1 (es)
MX (1) MX9705025A (es)
WO (1) WO1997016206A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6280956B1 (en) 1995-11-03 2001-08-28 University Of Pittsburgh Antibodies to bladder cancer nuclear matrix proteins and their use
US6232443B1 (en) 1997-04-08 2001-05-15 University Of Pittsburgh Renal nuclear matrix proteins, polynucleotide sequences encoding them, and their use
WO1998051824A1 (en) * 1997-05-15 1998-11-19 Abbott Laboratories Reagents and methods useful for detecting disease of the urinary tract
WO1998055656A1 (en) * 1997-06-05 1998-12-10 Abbott Laboratories Reagents and methods useful for detecting diseases of the urinary tract
WO1999002734A1 (en) * 1997-07-08 1999-01-21 Abbott Laboratories Reagents and methods useful for detecting diseases of the urinary tract
AU3316600A (en) 1999-02-22 2000-09-21 Torben F. Orntoft Gene expression in bladder tumors
US20030228640A1 (en) * 1999-10-15 2003-12-11 University Of Pittsburgh Nuclear matrix proteins, polynucleotide sequences encoding them, and their use
US6617432B1 (en) * 1999-10-15 2003-09-09 University Of Pittsburgh Nuclear matrix proteins polynucleotide sequences encoding them and their use
US20040076955A1 (en) * 2001-07-03 2004-04-22 Eos Biotechnology, Inc. Methods of diagnosis of bladder cancer, compositions and methods of screening for modulators of bladder cancer
WO2006026714A2 (en) * 2004-08-31 2006-03-09 Board Of Regents, The University Of Texas System Diagnosis and prognosis of cancer based on telomere length as measured on cytological specimens
WO2006060643A2 (en) * 2004-12-03 2006-06-08 University Of Pittsburgh Novel bladder matrix protein peptides and methods of detection of bladder cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4882268A (en) * 1985-12-24 1989-11-21 Massachusetts Institute Of Technology Method for determining tissue of origin and degree of malignancy of tumor cells
US5273877A (en) * 1985-12-24 1993-12-28 Massachusetts Institute Of Technology Non-histological cell type determination
JP3190042B2 (ja) * 1991-10-31 2001-07-16 マトリテク インコーポレイテッド 核マトリックス蛋白液アッセー
JPH07509602A (ja) * 1992-06-22 1995-10-26 マトリテク　インコーポレイテッド 新規な悪性細胞型内部核マトリックスマーカー
JPH08508396A (ja) * 1993-02-09 1996-09-10 ザ ジョーンズ ホプキンス ユニバーシティー スクール オブ メディシン 核マトリックスタンパク質
US5547928A (en) * 1993-12-17 1996-08-20 Matritech, Inc. Methods and compositions for the detection of colon cancers

Also Published As

Publication number Publication date
BR9607575A (pt) 1998-12-15
WO1997016206A8 (en) 1999-08-05
JPH10512158A (ja) 1998-11-24
US5866535A (en) 1999-02-02
EP0810874A1 (en) 1997-12-10
WO1997016206A1 (en) 1997-05-09
EP0810874A4 (en) 1998-12-16
CA2209314A1 (en) 1997-05-09
AU7474696A (en) 1997-05-22

Similar Documents

Publication Publication Date Title
EP0684955A4 (en) NUCLEAR MATRIX PROTEINS.
DE69841038D1 (es)
MX9705025A (es) Proteinas de matriz nuclear de vejiga y su uso para detectar y tratar trastornos proliferativos celulares.
HK1022480A1 (en) Porcine factor viii and hybrids thereof
EP1082433A4 (en) Interleukins 21 and 22
WO1999024463A3 (en) Signal peptide-containing proteins
GR3029740T3 (en) Fragments of prion proteins.
PL332431A1 (en) High protein expression level
EP0182372A3 (en) New factor viii coagulant polypeptides
NO892033D0 (no) Fibronectinbindende protein.
DK1086225T3 (da) Humant tumorafledt polypeptidhormon phosphatonin
MX9602977A (es) Proteinas que reparan la mala union de adn humano.
AU3072799A (en) Cytokine receptor common gamma chain like
DE69333954D1 (de) An der streptogramin biosynthese beteiligte polypeptide, ihre kodierenden nukleotidsequenzen und ihre verwendung
PL329618A1 (en) Novel peptides for use in an antigenm-specific immunosupressive therapy
WO1999033870A3 (en) Human regulatory proteins
EP1132402A4 (en) PEPTIDE FRAGMENTS WITH CELL DEATH PREVENTIVE ACTIVITY
PT773999E (pt) Receptor orfao or-1 pertencente a familia de receptores nucleares
AU5327198A (en) Nucleotide sequence coding for a flavin-containing monooxygenase, corresponding protein and their applications in the fields of diagnosis and therapy
MY127669A (en) Polypeptide hormone phosphatonin
WO2001029218A3 (en) Nuclear matrix proteins, polynucleotide sequences encoding them, and their use
WO2000012545A3 (en) Antibodies specific for bladder nuclear matrix proteins blca-1 to blca-6
WO1999021994A3 (en) Human vesicle membrane protein-like proteins
WO2006060643A3 (en) Novel bladder matrix protein peptides and methods of detection of bladder cancer
ATE183238T1 (de) Expressionsvektor für menschliche topoisomerase i